CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD

Cell Cycle

Volumn 11, Issue 21, 2012, Pages 4040-4046

  Bukanov, Nikolay O ^a   Moreno, Sarah E ^a   Natoli, Thomas A ^a   Rogers, Kelly A ^a   Smith, Laurie A ^a   Ledbetter, Steven R ^a   Oumata, Nassima ^b   Galons, Hervé ^c   Meijer, Laurent ^b   Ibraghimov Beskrovnaya, Oxana ^a  

^a SANOFI   (France)

^b Centre de Perharidy   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Animal model; Apoptosis; Cell cycle; Cell division; Cyclin dependent kinases; Proliferation; Therapy

Indexed keywords

CR 8; CYCLIN DEPENDENT KINASE INHIBITOR; ROSCOVITINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; EUKARYOTIC FLAGELLUM; FEMALE; KIDNEY CYST; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LIVER CYST; MOUSE; NONHUMAN;

EID: 84869398488     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22375     Document Type: Article

References (50)

1. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2011; 7:556-66; PMID:21862990; http://dx.doi.org/10.1038/nrneph.2011.109.
2. Takiar V, Caplan MJ. Polycystic kidney disease: pathogenesis and potential therapies. Biochim Biophys Acta 2011; 1812:1337-43; PMID:21146605; http://dx.doi.org/10.1016/j.bbadis.2010.11.014.
3. Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4:1140-50; PMID:19443627; http://dx.doi.org/10.2215/CJN.00790209.
4. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009; 60:321-37; PMID:18947299; http://dx.doi.org/10.1146/annurev.med.60.101707. 125712.
5. Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San Millán JL, et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 1995; 10:151-60; PMID:7663510; http://dx.doi.org/10.1038/ng0695-151.
6. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272:1339-42; PMID:8650545; http://dx.doi.org/10.1126/ science.272.5266.1339.
7. Chang MY, Ong AC. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract 2012; 120:c25-34, discussion c35; PMID:22205396; http://dx.doi.org/10. 1159/000334166.
8. Leuenroth SJ, Crews CM. Targeting cyst initiation in ADPKD. J Am Soc Nephrol 2009; 20:1-3; PMID:19118147; http://dx.doi.org/10.1681/ASN.2008101118.
9. Wilson PD, Goilav B. Cystic disease of the kidney. Annu Rev Pathol 2007; 2:341-68; PMID:18039103; http://dx.doi.org/10.1146/annurev.pathol.2.010506. 091850.
10. Goilav B. Apoptosis in polycystic kidney disease. Biochim Biophys Acta 2011; 1812:1272-80; PMID:21241798; http://dx.doi.org/10.1016/j.bbadis.2011.01. 006.
11. Gallagher AR, Germino GG, Somlo S. Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17:118- 30; PMID:20219615; http://dx.doi.org/10.1053/j.ackd.2010.01.002.
12. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76:149-68; PMID:19455193; http://dx.doi.org/10. 1038/ki.2009.128.
13. Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP. Tolvaptan inhibits ERK-dependent cell proliferation, Cl- secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 2011; 301:F1005-13; PMID:21816754; http://dx.doi.org/10.1152/ajprenal. 00243.2011.
14. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10:363-4; PMID:14991049; http://dx.doi.org/10.1038/ nm1004.
15. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, et al.; TEMPOFormula and 156-05-002 Study Investigators. Tolvaptan in autosomal dominant polycystic kidney disease: three years'experience. Clin J Am Soc Nephrol 2011; 6:2499-507; PMID:21903984; http://dx.doi.org/10.2215/CJN.03530411.
16. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21:1052-61; PMID:20431041; http://dx.doi.org/10.1681/ASN.2009121291.
17. Shillingford JM, Piontek KB, Germino GG, Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 2010; 21:489-97; PMID:20075061; http://dx.doi.org/10.1681/ASN.2009040421.
18. Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363:830-40; PMID:20581392; http://dx.doi.org/10.1056/ NEJMoa1003491.
19. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363:820-9; PMID:20581391; http://dx.doi.org/10.1056/ NEJMoa0907419.
20. Sweeney WE Jr., von Vigier RO, Frost P, Avner ED. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 2008; 19:1331-41; PMID:18385429; http://dx.doi.org/10.1681/ASN.2007060665.
21. Pazour GJ, Dickert BL, Vucica Y, Seeley ES, Rosenbaum JL, Witman GB, et al. Chlamydomonas IFT88 and its mouse homologue, polycystic kidney disease gene tg737, are required for assembly of cilia and flagella. J Cell Biol 2000; 151:709-18; PMID:11062270; http://dx.doi.org/10.1083/jcb.151.3.709.
22. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 2002; 13:2508-16; PMID:12239239; http://dx.doi.org/10.1097/01.ASN.0000029587.47950.25.
23. Hildebrandt F, Otto E. Cilia and centrosomes: a unifying pathogenic concept for cystic kidney disease? Nat Rev Genet 2005; 6:928-40; PMID:16341073; http://dx.doi.org/10.1038/nrg1727.
24. Battini L, Macip S, Fedorova E, Dikman S, Somlo S, Montagna C, et al. Loss of polycystin-1 causes centrosome amplification and genomic instability. Hum Mol Genet 2008; 17:2819-33; PMID:18566106; http://dx.doi.org/10.1093/hmg/ ddn180.
25. Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, et al. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 2002; 109:157-68; PMID:12007403; http://dx.doi.org/10.1016/S0092-8674(02)00716-X.
26. Li X, Luo Y, Starremans PG, McNamara CA, Pei Y, Zhou J. Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. Nat Cell Biol 2005; 7:1202-12; PMID:16311606; http://dx.doi.org/10.1038/ ncb1326.
27. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243:527-36; PMID:9030781; http://dx.doi.org/10.1111/j.1432-1033.1997.t01- 2-00527.x.
28. Meijer L, Bettayeb K, Galons H. Roscovitine (CYC202, Seliciclib). In: Yue E, Smith PJ, eds. Monographs on enzyme inhibitors: CDK inhibitors and their potential as antitumor agents: CRC Press, Taylor & Francis, 2006:187-226.
29. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006; 444:949-52; PMID:17122773; http://dx.doi.org/10.1038/ nature05348.
30. Moreno S, Ibraghimov-Beskrovnaya O, Bukanov NO. Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD. Cell Cycle 2008; 7:1856-64; PMID:18583937; http://dx.doi.org/10.4161/cc.7.12.6055.
31. Ibraghimov-Beskrovnaya O. Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle 2007; 6:776-9; PMID:17377490; http://dx.doi.org/10.4161/cc.6.7.4047.
32. Natoli TA, Smith LA, Rogers KA, Wang B, Komarnitsky S, Budman Y, et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med 2010; 16:788-92; PMID:20562878; http://dx.doi.org/10.1038/nm.2171.
33. Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008; 27:5797-807; PMID:18574471; http://dx.doi.org/10.1038/onc.2008.191.
34. Bettayeb K, Baunbæk D, Delehouze C, Loaëc N, Hole AJ, Baumli S, et al. CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer 2010; 1:369-80; PMID:21779453; http://dx.doi.org/10.1177/1947601910369817.
35. O Bukanov N, Husson H, Dackowski WR, Lawrence BD, Clow PA, Roberts BL, et al. Functional polycystin- 1 expression is developmentally regulated during epithelial morphogenesis in vitro: downregulation and loss of membrane localization during cystogenesis. Hum Mol Genet 2002; 11:923-36; PMID:11971874; http://dx.doi.org/10.1093/hmg/11.8.923.
36. Belibi FA, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs 2010; 19:315-28; PMID:20141351; http://dx.doi.org/10.1517/13543781003588491.
37. Lee K, Battini L, Gusella GL. Cilium, centrosome and cell cycle regulation in polycystic kidney disease. Biochim Biophys Acta 2011; 1812:1263-71; PMID:21376807; http://dx.doi.org/10.1016/j.bbadis.2011.02.008.
38. Zhou J. Polycystins and primary cilia: primers for cell cycle progression. Annu Rev Physiol 2009; 71:83-113; PMID:19572811; http://dx.doi.org/10.1146/annurev.physiol.70.113006.100621.
39. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005; 280:31208-19; PMID:15975926; http://dx.doi.org/10.1074/jbc.M500806200.
40. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 96:29-37; PMID:17179992; http://dx.doi.org/10.1038/sj. bjc.6603509.
41. Fedorov LM, Schmittwolf C, Amann K, Thomas WH,Müller AM, Schubert H, et al. Renal failure causes early death of bcl-2 deficient mice. Mech Ageing Dev 2006; 127:600-9; PMID:16620920; http://dx.doi.org/10.1016/j.mad.2006.02.009.
42. Moser M, Dahmen S, Kluge R, Gröne H, Dahmen J, Kunz D, et al. Terminal renal failure in mice lacking transcription factor AP-2 beta. Lab Invest 2003; 83:571-8; PMID:12695560.
43. Lin HH, Yang TP, Jiang ST, Yang HY, Tang MJ. Bcl-2 overexpression prevents apoptosis-induced Madin-Darby canine kidney simple epithelial cyst formation. Kidney Int 1999; 55:168-78; PMID:9893125; http://dx.doi.org/10.1046/ j.1523-1755.1999.00249.x.
44. Tao Y, Kim J, Faubel S, Wu JC, Falk SA, Schrier RW, et al. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci USA 2005; 102:6954-9; PMID:15863619; http://dx.doi. org/10.1073/pnas.0408518102.
45. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103:5466-71; PMID:16567633; http://dx.doi.org/10.1073/pnas.0509694103.
46. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Masyuk AI, Gradilone SA, et al. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology 2012; 142:622-33, e4; PMID:22155366; http://dx.doi.org/10.1053/j.gastro.2011.11.036.
47. Natoli TA, Gareski TC, Dackowski WR, Smith L, Bukanov NO, Russo RJ, et al. Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures. Am J Physiol Renal Physiol 2008; 294:F73-83; PMID:17928412; http://dx.doi.org/10.1152/ajprenal.00362.2007.
48. Seibler J, Zevnik B, Küter-Luks B, Andreas S, Kern H, Hennek T, et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res 2003; 31:e12; PMID:12582257; http://dx.doi.org/10.1093/nar/gng012.
49. Oumata N, Bettayeb K, Ferandin Y, Demange L, Lopez-Giral A, Goddard ML, et al. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J Med Chem 2008; 51:5229-42; PMID:18698753; http://dx.doi.org/10.1021/jm800109e.
50. Oumata N, Ferandin Y, Meijer L, Galons H. Practical synthesis of roscovitine and CR8. Org Process Res Dev 2009; 13:641-4; http://dx.doi.org/10. 1021/op800284k.